搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
centerforbiosimilars
14 小时
Ashling Wahner
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf ...
centerforbiosimilars
2 天
The Top 5 Most-Read Gastroenterology Articles of 2024
The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...
centerforbiosimilars
1 天
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, ...
centerforbiosimilars
6 天
Study Shows Biosimilarity of Bevacizumab Biosimilar in CRC
A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) ...
centerforbiosimilars
5 天
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared ...
centerforbiosimilars
9 天
Trastuzumab’s Evergreening Impact on Biosimilars, Health Care Costs
The impact of pharmaceutical companies' evergreening strategies on the adoption of trastuzumab biosimilars in the Netherlands ...
centerforbiosimilars
4 天
China's Biosimilar Market: Trastuzumab Uptake and Future Trends
China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing ...
centerforbiosimilars
6 天
Health Canada Approves First Omalizumab Biosimilar
Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic ...
centerforbiosimilars
12 天
BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for ...
The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a ...
centerforbiosimilars
10 天
The Top 5 Biosimilar Articles for the Week of December 9
Number 5: Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...
centerforbiosimilars
13 天
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas ...
Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat ...
centerforbiosimilars
15 天
AI-Powered Solutions for Streamlining Biosimilar Prescribing and Monitoring
Steve Pickette, PharmD, BCPS, emphasizes that AI can streamline prescribing and formulary management for biosimilars and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈